Psychopharmacology in cancer

Curr Psychiatry Rep. 2015 Jan;17(1):529. doi: 10.1007/s11920-014-0529-x.

Abstract

Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient's quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.

Publication types

  • Review

MeSH terms

  • Humans
  • Mental Disorders / complications*
  • Mental Disorders / drug therapy*
  • Mental Disorders / psychology
  • Neoplasms / complications*
  • Neoplasms / psychology
  • Psychopharmacology / methods
  • Psychotropic Drugs / therapeutic use*
  • Sleep Wake Disorders / complications
  • Sleep Wake Disorders / drug therapy
  • Sleep Wake Disorders / psychology

Substances

  • Psychotropic Drugs